Summary

doi: 10.25005/2074-0581-2016-18-3-42-46
INFLUENCE OF IMMUNOMODULATORY THERAPY ON THE HEMATOPOIESIS IN PATIENTS WITH DISSEMINATED CANCER OF BREAST

D.S. Mirzoyeva, A.D. Zikiryahojaev, G.M. Bobizoda

State Institution «National Cancer Research Center» the MH and SSP of the Republic of Tajikistan

The authors are presented the results of treatment 86 patients with metastatic breast cancer (MBC), who had a metastatic lesion of various organs. In terms of palliative care used chemoradiation.

Administeredof immunomodulatorsin treatment regimens improved such parameters as hemoglobin, red blood cells, platelets, leukocytes, segmented neutrophils and monocytes. Effects on other blood indicators were mixed.

In each group, patients had light degree of anemia – although hemoglobin was lower than normal, but it was more than 90 g/l. On this basis, the largest increase in hemoglobin observed Thymogarapplying (with 107,75±5,57 g/l to 122,25±5,85 g/l), then – Thymofer (from 93,35±2,72 g/l to 104,29±2,5 g/l) and the lowest – Thymosine (s 117,66±1,8 g/l to 123,08±1,78 g/l). When the number of red blood cells increasing the sequence of drug activity was different: the most active proved Thymogar (from 3,55±0,18 to 4,09±0,2 x 1012), then Thymosine (from 3,79±0,11 to 4,08±0,06 x 1012) and Thymofer (from 3,2±0,096 to 3,39±0,12 x 1012).

Thus, all three immunomodulatory drugs help reduce the severity of anemia in patients MBC, at that the «Thymogar» and «Thymosine» are best drugs.

Keywords: disseminated breast cancer, chemoradiation, immunomodulators (Thymogar, Thymosine, Thymofer).

Download file:


Materials on the topic: